文献速递湿疹皮炎与荨麻疹

AlphaFold3与分子动力学模拟区分OX40与OX40L靶向生物制剂的分子机制

Molecular differentiation of OX40- and OX40L-targeted biologics using AlphaFold3 and molecular dynamics simulations.
PubMed 文献 · J Invest Dermatol · 2026-02-04

研究采用AlphaFold3与分子动力学模拟预测OX40靶向抗体rocatinlimab、telazorlimab及OX40L靶向抗体amlitelimab与靶点的共复合物结构,并计算结合自由能。结果显示rocatinlimab与amlitelimab通过空间位阻直接阻断OX40-OX40L相互作用,而telazorlimab破坏关键的OX40-OX40L键。

要点

  • rocatinlimab与amlitelimab通过空间位阻直接阻断OX40-OX40L界面。
  • telazorlimab通过破坏关键的OX40-OX40L键来干扰信号。
  • 计算模型为理解这些生物制剂的表位与作用机制提供了分子层面特征。

核心结论

  • rocatinlimab和amlitelimab通过物理阻断OX40-OX40L天然界面发挥空间位阻抑制作用。
  • telazorlimab通过破坏关键的OX40-OX40L键来干扰OX40-OX40L信号。

研究设计与样本

  • 采用计算建模预测抗体-蛋白共复合物并表征相互作用界面。
  • 使用MM-PBSA与逐残基能量分解分析抗体结合界面5 Å内的特定残基-残基相互作用结合自由能。

主要发现

  • rocatinlimab和amlitelimab直接抑制OX40-OX40L相互作用,机制为空间位阻阻断天然界面。
  • telazorlimab破坏关键的OX40-OX40L键。

临床怎么用

  • 为皮肤科中新兴的OX40与OX40L靶向生物制剂提供表位的分子特征描述。
  • 有助于理解不同抗体在阻断OX40-OX40L信号上的机制差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis is a chronic inflammatory skin disorder that affects over 200 million people worldwide. Although disease etiology is multifaceted, the immune checkpoint molecules OX40 and OX40L have a critical role in disease development. Recent clinical trials demonstrated that the OX40-targeting antibodies rocatinlimab (KHK4083/AMG-451) and telazorlimab (GBR-830/ISB-830) and the OX40L-targeting antibody amlitelimab (KY1005) significantly improve symptoms of atopic dermatitis. However, the epitopes where these antibodies bind OX40 and OX40L remain unclear, and therefore, so do the mechanisms through which they specifically disrupt OX40-OX40L signaling. To address this, computational modeling was performed to predict antibody-protein cocomplexes, and their interaction interfaces were characterized. Binding-free energy of specific OX40 or OX40L residue-residue interactions within 5 Å of the antibody binding interface was analyzed using Molecular Mechanics Poisson-Boltzmann Surface Area with a per-residue energy decomposition analysis. Our analysis suggests that rocatinlimab and amlitelimab directly inhibit OX40-OX40L interactions by physically blocking the cognate OX40-OX40L interface through steric occlusion, whereas telazorlimab disrupts a critical OX40-OX40L bond. Together, this work provides molecular characterization of the epitopes of OX40- and OX40L-targeted biologics emerging in dermatology.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Nolden K, Shi Y, Batista VS, et al. Molecular differentiation of OX40- and OX40L-targeted biologics using AlphaFold3 and molecular dynamics simulations. J Invest Dermatol. 2026. PMID: 41651107. doi:10.1016/j.jid.2026.01.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。